183551-10-2

Basic information

• Product Name: 1-Propanol, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-
• CAS NO: 183551-10-2
• Molecular Formula: C12H13F6NO
• Molecular Weight: 301.232
• Mol File: 183551-10-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Propanol, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanol, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-(183551-10-2)
• EPA Substance Registry System: 1-Propanol, 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-(183551-10-2)

Safety Data

• Hazardous Substances Data: 183551-10-2(Hazardous Substances Data)

Upstream product

• 183551-52-2 2-chloro-5-methyl-4-phenylnicotinic acid 
• 401-95-6 3,5-Bis(trifluoromethyl)benzaldehyde 
• 32707-89-4 3,5-bis(trifluoromethyl)benzenemethanol 

Downstream Products

• 569683-98-3 6-[3,5-bis(trifluoromethyl)benzyl]-4-chloro-2-methylthio-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one 
• 183551-61-3 N-[3,5-bis(trifluoromethyl)benzyl]-2-chloro-N-(3-hydroxypropyl)-6-methyl-4-phenylnicotinamide 
• 544671-79-6 N-[3,5-bis(trifluoromethyl)benzyl]-2-chloro-N-(3-hydroxypropyl)-4-iodo-3-pyridinecarboxamide 
• 544671-92-3 5-[3,5-bis(trifluoromethyl)benzyl]-9-chloro-7-phenyl-3,4,5,6-tetrahydro-2H-pyrido[2,3-b]-1,5-oxazocin-6-one 
• 544671-86-5 5-[3,5-bis(trifluoromethyl)benzyl]-10-oxo-7-phenyl-3,4,5,6-tetrahydro-2H-pyrido[2,3-b]-1,5-oxazocin-6-one 
• 544671-80-9 5-[3,5-bis(trifluoromethyl)benzyl]-7-iodo-3,4,5,6-tetrahydro-2H-pyrido[2,3-b]-1,5-oxazocin-6-one 
• 544671-66-1 9-(4-aminopiperidine-1-yl)-5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine 
• 569684-14-6 5-[3,5-bis(trifluoromethyl)benzyl]-7-(4-fluorophenyl)-9-(methylsulfonyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine 
• 847159-13-1 N-[3,5-bis(trifluoromethyl)phenylmethyl]-N-(3-hydroxypropyl)-4-chloro-6-(2-methylphenyl)-2-methylthiopyrimidine-5-carboxamide 
• 183549-97-5 5-[3,5-bis(trifluoromethyl)benzyl]-7-phenyl-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocin-6-one 
• 183551-12-4 N-[3,5-bis(trifluoromethyl)benzyl]-2-chloro-N-(3-hydroxypropyl)-5-methyl-4-phenylnicotinamide 
• 183551-09-9 N-[3,5-Bis(trifluoromethyl)benzyl]-2-chloro-N-(3-hydroxypropyl)-4-phenyl-3-pyridinecarboxamide 

Relevant articles and documents

Enantioselective Radical Cyclization for Construction of 5-Membered Ring Structures by Metalloradical C-H Alkylation

Radical cyclization represents a powerful strategy for construction of ring structures. Traditional radical cyclization, which is based on radical addition as the key step, necessitates the use of unsaturated substrates. Guided by the concept of metalloradical catalysis, a different mode of radical cyclization that can employ saturated C-H substrates is demonstrated through the development of a Co(II)-based system for catalytic activation of aliphatic diazo compounds for enantioselective radical alkylation of various C(sp3)-H bonds. It allows for efficient construction of chiral pyrrolidines and other valuable 5-membered cyclic compounds. This alternative strategy of radical cyclization provides a new retrosynthetic paradigm to prepare five-membered cyclic molecules from readily available open-chain aldehydes through the union of C-H and C=O elements for C-C bond formation.

DRUGS

The present invention relates to a medicine which comprises a compound (I) of the formula:[wherein the ring M is a heterocylic ring having -N=Ca and Rb are bound to each other to form the ring A, or they are the same or different each representing a hydrogen atom or a substituent on the ring M;the rings A and B each is an optionally substituted homocycle or heterocycle, and at least one of them is an optionally substituted heterocycle;the ring C is an optionally substituted homocycle or heterocycle;the ring Z is an optionally substituted nitrogen-containing heterocycle; andn is an integer of 1 to 6] or a salt thereof in combination with a drug having an emetic action. The compounds (I) or their salts are useful as anti-emetic drugs. Particularly, vomiting caused by drugs having an emetic action can be inhibited by these compounds rapidly and safely at a low dose.